<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456309</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2020/DR-02</org_study_id>
    <nct_id>NCT04456309</nct_id>
  </id_info>
  <brief_title>Brain MRI in Stroke Patients With Intracardiac Thrombus</brief_title>
  <acronym>BRAIN IRM</acronym>
  <official_title>Brain MRI Characteristics in Stroke Patients With Intracardiac Thrombus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In earlier reports, infarction of cardioembolic origin has been associated with acute lesions
      involving the cortex, and with multiple acute lesions in single or multiple cerebral
      circulation territories, and small (most often chronic and asymptomatic) cortical cerebellar
      infarctions (SCCI). Our aim was to analyse brain MRI characteristics in patients presenting
      with acute infarction associated with intracardiac thrombus, and to compare them with stroke
      patients with atrial fibrillation (AF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>brain MRI diffusion-weighted imaging for the acute symptomatic infarction Both groups</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>infarction location ((anterior/middle/posterior cerebral artery; brainstem or cerebellum [SCCI or non-SCCI] involvement; anterior, posterior, or mixed anterior-posterior circulation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>brain MRI diffusion-weighted imaging for the acute symptomatic infarction Both groups</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>presence of multiterritorial infarction (mixed anterior-posterior circulation or bilateral anterior circulation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>brain MRI diffusion-weighted imaging for the acute symptomatic infarction Both groups</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>number of infarction lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>brain MRI diffusion-weighted imaging for the acute symptomatic infarction Both groups</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>the cortical/subcortical/corticosubcortical location of infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>brain MRI diffusion-weighted imaging for the acute symptomatic infarction Both groups</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>the size of subcortical lesion (&lt; or &gt;15 mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>brain MRI diffusion-weighted imaging for the acute symptomatic infarction Both groups</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>the infarction volume (DWI volume and ASPECT score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain MRI for the group with intracardiac thrombus</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>Localisation of the thrombus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain MRI for the group with intracardiac thrombus</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>the size of the thrombus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain MRI for the group with intracardiac thrombus</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>The associated echocardiographic abnormalities (dilated atrium of ventricle, ejection fraction, hypokinesia)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain MRI for the group with intracardiac thrombus</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>the presence of associated AF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain MRI for the group with intracardiac thrombus</measure>
    <time_frame>Day of inclusion (Day 1)</time_frame>
    <description>the time interval between the brain MRI performance and the identification of the intracardiac thrombus</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Stroke</condition>
  <condition>Intracardiac Thrombus</condition>
  <arm_group>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <description>stroke Patients with atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intracardiac thrombus</arm_group_label>
    <description>stroke Patients with intracardiac thrombus</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention,</intervention_name>
    <description>pure observational study</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>intracardiac thrombus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        2 groups of patients :

        1 - Stroke patients with atrial fibrillation

        2- Stroke patients with intracardiac thrombus
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients, recruited and registered in the stroke database between June
             2018 and November 2019 of our center (Nîmes University Hospital, France), presenting
             with acute symptomatic infarction (confirmed by diffusion-weighted MRI) associated
             with intracardiac thrombus or with with known or newly discovered AF

          -  Patients with MRI as part of their diagnostic work-up within one week after symptom
             onset (including diffusion-weighted imaging, intra- [TOF, gadolinium-enhanced MRA,
             and/or CTA] and extracranial [gadolinium-enhanced MRA, CTA, and/or duplex ultrasound]
             vessel imaging, contrast transoesophageal or contrast transthoracic echocardiography,
             and ≥24h ECG monitoring (acute stroke unit monitoring and/or Holter monitoring)

        Exclusion Criteria:

          -  opt-out patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitri RENARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dimitri RENARD, Dr</last_name>
    <phone>+33 4 66 68 32 61</phone>
    <email>dimitri.renard@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri RENARD</last_name>
      <phone>+33 4 66 68 32 61</phone>
      <email>dimitri.renard@chu-nimes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

